Keeping Track: AstraZeneca Wins Approval For Lumoxiti, AbbVie Expands Label For Venclexta With MRD Data, and FDA Delays Acorda's Inbrijia NDA

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

The US FDA approved AstraZeneca PLC's CD22-directed cytotoxin Lumoxiti (moxetumomab pasudotox-tdfk), which became novel agent No. 36 backed by the Center for Drug Evaluation and Research (CDER) in 2018. It was also the first September approval for a novel drug, in what appears will be a quiet month compared with the recent and upcoming months.

AbbVie Inc. grew its label for Venclexta (venetoclax tablets) by adding minimal residual disease (MRD)-negativity data to the label...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet